<DOC>
	<DOCNO>NCT01475006</DOCNO>
	<brief_summary>This open-label , sequential dose exploration study single agent AMG 595 administer subject recurrent glioblastoma multiforme ( GBM ) and/or anaplastic astrocytomas ( AA ) . The purpose study evaluate safety , tolerability , pharmacokinetics ( PK ) AMG 595 , also evaluate objective response rate subject receive AMG 595 . This study conduct two part . Part 1 explore dos AMG 595 subject recurrent GBM and/or AA . Part 2 ( dose expansion ) examine MTD establish Part 1 subject recurrent GBM .</brief_summary>
	<brief_title>AMG 595 First-in-Human Recurrent Gliomas</brief_title>
	<detailed_description>This study AMG 595 conduct two part : Part 1 ( dose exploration ) Part 2 ( dose expansion ) . Part 1 study subject recurrent glioblastoma multiforme ( GBM ) and/or anaplastic astrocytomas ( AA ) , Part 2 examine MTD subject recurrent GBM . Approximately 30-40 subject may enrol Part 1 , 36 subject may enrol Part 2 . The dose AMG 595 utilized Part 2 dependent upon data obtain Part 1 study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<criteria>Karnofsky performance score &gt; = 70 % Must pathologically document , definitively diagnosed recurrent WHO Grade IV advance malignant glioblastoma multiforme ( Part 1 Part 2 ) and/or WHO Grade III anaplastic astrocytoma ( Part 1 ) . GBM and/or AA tumor express EGFRvIII assess archived tissue IHC stain section contain minimum 100 evaluable tumor cell . Archived tumor tissue initial diagnosis subsequent relapse ( ) Grade IV advance malignant glioblastoma multiforme Grade III anaplastic astrocytoma available submission central review . Subjects recurrent disease ( confirm MRI evaluable Macdonald criterion ) time first second recurrence progression follow initial definitive therapy ( ) QTcF ≤ 470 msec Hematological function , follow : Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L , Platelet count ≥ 100 x 10^9/L , Hemoglobin &gt; 9 g/dL Renal function , follow : Estimated glomerular filtration rate use Modified Diet Renal Disease ( MDRD ) equation &gt; 45 mL/min/1.73m^2 , Urinary protein quantitative value &lt; 30 mg/dL urinalysis ≤ 1+ dipstick , unless quantitative protein &lt; 500 mg 24 hr urine sample History central nervous system bleed define stroke intraocular bleed ( include embolic stroke ) within 6 month enrollment . Evidence acute intracranial / intratumoral hemorrhage , except subject stable grade 1 hemorrhage . Peripheral sensory neuropathy &gt; Grade 2 . Clinically significant ECG change obscure ability ass PR , QT , QRS interval ; congenital long QT syndrome . Recent infection require intravenous antiinfective treatment complete ≤ 14 day enrollment . Received radiation therapy within 12 week enrollment recover toxic effect therapy . For Part 1 ( dose escalation ) : Treatment bevacizumab antiangiogenic therapy within 4 week enrollment , Part 2 ( dose expansion ) : prior treatment bevacizumab antiangiogenic therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Epidermal Growth Factor Receptor Variant III</keyword>
	<keyword>EGFRvIII</keyword>
	<keyword>Glioma</keyword>
	<keyword>Anaplastic Astrocytomas</keyword>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>Antibody drug conjugate</keyword>
	<keyword>brain tumor</keyword>
</DOC>